Please use this identifier to cite or link to this item:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/88229Full metadata record
| ???org.dspace.app.webui.jsptag.ItemTag.dcfield??? | Value | Language |
|---|---|---|
| dc.contributor.advisor | 王尚麟 | zh_TW |
| dc.contributor.advisor | Shang-Lin Wang | en |
| dc.contributor.author | 熊紀梅 | zh_TW |
| dc.contributor.author | Chi-Mei Hsiung | en |
| dc.date.accessioned | 2023-08-09T16:06:40Z | - |
| dc.date.available | 2023-11-09 | - |
| dc.date.copyright | 2023-08-09 | - |
| dc.date.issued | 2023 | - |
| dc.date.submitted | 2023-07-18 | - |
| dc.identifier.citation | 1. Vail DM, Thamm DH, Liptak JM. Hematopoietic tumors. Withrow and MacEwen's Small Animal Clinical Oncology. 2019:688-710.
2. Seelig DM, Avery AC, Ehrhart E, Linden MA. The comparative diagnostic features of canine and human lymphoma. Veterinary Sciences. 2016;3(2):11. 3. Teske E. Canine malignant lymphoma: A review and comparison with human non‐hodgkin's lymphoma. Veterinary Quarterly. 1994;16(4):209-219. 4. Pastor M, Chalvet‐Monfray K, Marchal T, Keck G, Magnol J, Fournel‐Fleury C, et al. Genetic and environmental risk indicators in canine non‐hodgkin's lymphomas: Breed associations and geographic distribution of 608 cases diagnosed throughout france over 1 year. Journal of Veterinary Internal Medicine. 2009;23(2):301-310. 5. Zanini DA, Kimura KC, Nishiya AT, Ubukata R, Leandro RM, Brito CPD, et al. Environmental risk factors related to the development of canine non-hodgkin's lymphoma. Ciência Rural. 2013;43:1302-1308. 6. Zandvliet M. Canine lymphoma: A review. Veterinary Quarterly. 2016;36(2):76-104. 7. Villamil JA, Henry CJ, Hahn AW, Bryan JN, Tyler JW, Caldwell CW. Hormonal and sex impact on the epidemiology of canine lymphoma. Journal of cancer epidemiology. 2009;2009. 8. Montaner-Angoiti E, Marín-García PJ, Llobat L. Epigenetic alterations in canine malignant lymphoma: Future and clinical outcomes. Animals. 2023;13(3):468. 9. Gustafson DL, Bailey DB. Cancer chemotherapy. Withrow and MacEwen’s Small Animal Clinical Oncology. 2019:182-208. 10. Park HJ, Kim JW, Song KH, Seo KW. Application of vincristine-loaded platelet therapy in three dogs with refractory immune-mediated thrombocytopenia. Journal of Veterinary Science. 2015;16(1):127-130. 11. Ahn YS, Byrnes JJ, Harrington WJ, Cayer ML, Smith DS, Brunskill DE, et al. The treatment of idiopathic thrombocytopenia with vinblastine-loaded platelets. New England Journal of Medicine. 1978;298(20):1101-1107. 12. Mammadova-Bach E, Mangin P, Lanza F, Gachet F. Platelets in cancer. Hämostaseologie. 2015;35(04):325-336. 13. Harvey JW. Chapter 7 - evaluation of hemostasis: Coagulation and platelet disorders. Veterinary Hematology. 2012:191-233. 14. Braun A, Anders HJ, Gudermann T, Mammadova-Bach E. Platelet-cancer interplay: Molecular mechanisms and new therapeutic avenues. Frontiers in Oncology. 2021;11:665534. 15. Haemmerle M, Stone RL, Menter DG, Afshar-Kharghan V, Sood AK. The platelet lifeline to cancer: Challenges and opportunities. Cancer cell. 2018;33(6):965-983. 16. Huang WH, Lee JJ, Liao AT, Wang SL. Paraneoplastic syndrome as a prognostic factor in dogs with multicentric lymphoma. International Journal of Applied Research in Veterinary Medicine. 2020;18(2):131-137. 17. Garrett LD, Thamm DH, Chun R, Dudley R, Vail DM. Evaluation of a 6‐month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. Journal of Veterinary Internal Medicine. 2002;16(6):704-709. 18. Wang SL, Lee J, Liao A. Chemotherapy-induced neutropenia is associated with prolonged remission duration and survival time in canine lymphoma. The Veterinary Journal. 2015;205(1):69-73. 19. Josa V, Krzystanek M, Eklund AC, Salamon F, Zarand A, Szallasi Z, et al. Relationship of postoperative thrombocytosis and survival of patients with colorectal cancer. International Journal of Surgery. 2015;18:1-6. 20. Campbell O, Macdonald V, Dickinson R, Gagnon J. Evaluation of the effect of vincristine on platelet count in dogs with lymphoma. Journal of Small Animal Practice. 2019;60(12):734-738. 21. Allen EC, Tarigo JL, Levine DN, Barber JP, Brainard BM. Platelet number and function in response to a single intravenous dose of vincristine. Journal of Veterinary Internal Medicine. 2021;35(4):1754-1762. 22. Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction. Proceedings of the National Academy of Sciences. 1968;61(1):46-52. 23. Bambace N, Holmes C. The platelet contribution to cancer progression. Journal of thrombosis and haemostasis. 2011;9(2):237-249. 24. Cho MS, Noh K, Haemmerle M, Li D, Park H, Hu Q, et al. Role of adp receptors on platelets in the growth of ovarian cancer. Blood, The Journal of the American Society of Hematology. 2017;130(10):1235-1242. 25. Giannakeas V, Kotsopoulos J, Cheung MC, Rosella L, Brooks JD, Lipscombe L, et al. Analysis of platelet count and new cancer diagnosis over a 10-year period. JAMA Network Open. 2022;5(1):e2141633. 26. Giannakeas V, Kotsopoulos J, Brooks JD, Cheung MC, Rosella L, Lipscombe L, et al. Platelet count and survival after cancer. Cancers. 2022;14(3):549. 27. Marconato L, Gelain ME, Comazzi S. The dog as a possible animal model for human non‐hodgkin lymphoma: A review. Hematological Oncology. 2013;31(1):1-9. 28. Chen H, Qin Y, Yang J, Liu P, He X, Zhou S, et al. The pretreatment platelet count predicts survival outcomes of diffuse large b-cell lymphoma: An analysis of 1007 patients in the rituximab era. Leukemia Research. 2021;110:106715. 29. Chen LP, Lin SJ, Yu MS. Prognostic value of platelet count in diffuse large b-cell lymphoma. Clinical Lymphoma Myeloma and Leukemia. 2012;12(1):32-37. 30. Zhao P, Zang L, Zhang X, Chen Y, Yue Z, Yang H, et al. Novel prognostic scoring system for diffuse large b-cell lymphoma. Oncology Letters. 2018;15(4):5325-5332. 31. Woolcock A, Keenan A, Cheung C, Christian J, Moore G. Thrombocytosis in 715 dogs (2011–2015). Journal of Veterinary Internal Medicine. 2017;31(6):1691-1699. 32. Henriques J, Felisberto R, Constantino‐Casas F, Cabeçadas J, Dobson J. Peripheral blood cell ratios as prognostic factors in canine diffuse large b‐cell lymphoma treated with chop protocol. Veterinary and Comparative Oncology. 2021;19(2):242-252. 33. Childress M, Ramos‐Vara J, Ruple A. Retrospective analysis of factors affecting clinical outcome following chop‐based chemotherapy in dogs with primary nodal diffuse large b‐cell lymphoma. Veterinary and Comparative Oncology. 2018;16(1):E159-E168. 34. Wu YF, Chu SC, Chang BS, Cheng YT, Wang TF. Hematologic markers as prognostic factors in nonmetastatic esophageal cancer patients under concurrent chemoradiotherapy. BioMed Research International. 2019;2019:11. 35. Giannakeas V. Trends in platelet count among cancer patients. Experimental Hematology & Oncology. 2022;11(1):16. 36. Kim MS, Baek SH, Noh JJ, Shim JI, Kang JH, Jeong SY, et al. Role of reactive thrombocytosis after primary cytoreductive surgery in advanced ovarian cancer. Frontiers in Oncology. 2022;12. 37. Vail D, Michels G, Khanna C, Selting K, London C, Group VCO. Response evaluation criteria for peripheral nodal lymphoma in dogs (v1. 0)–a veterinary cooperative oncology group (vcog) consensus document. Veterinary and Comparative Oncology. 2010;8(1):28-37. 38. Graff EC, Spangler EA, Smith A, Denhere M, Brauss M. Hematologic findings predictive of bone marrow disease in dogs with multicentric large‐cell lymphoma. Veterinary Clinical Pathology. 2014;43(4):505-512. 39. Riondato F, Martini V, Poggi A, Massaglia I, Comazzi S, Borrelli A, et al. Identification of peripheral blood involvement in dogs with large b-cell lymphoma: Comparison of different methods. Research in Veterinary Science. 2017;115:288-293. 40. Mackin AJ, Allen D, Johnston I. Effects of vincristine and prednisone on platelet numbers and function in clinically normal dogs. American Journal of Veterinary Research. 1995;56(1):100-108. 41. Keller ET. Immune‐mediated disease as a risk factor for canine lymphoma. Cancer. 1992;70(9):2334-2337. 42. Rozanski EA, Callan MB, Hughes D, Sanders N, Giger U. Comparison of platelet count recovery with use of vincristine and prednisone or prednisone alone for treatment for severe immune-mediated thrombocytopenia in dogs. Journal of The American Veterinary Medical Association. 2002;220(4):477-481. 43. Laquaglia KA, Robertson JB, Lunn KF. Neutropenia in dogs receiving vincristine for treatment of presumptive immune‐mediated thrombocytopenia. Journal of Veterinary Internal Medicine. 2021;35(1):226-233. 44. Mounce LT, Hamilton W, Bailey SE. Cancer incidence following a high-normal platelet count: Cohort study using electronic healthcare records from english primary care. British Journal of General Practice. 2020;70(698):e622-e628. 45. Mizutani H, Furubayashi T, Imai Y, Kashiwagi H, Honda S, Take H, et al. Mechanisms of corticosteroid action in immune thrombocytopenic purpura (itp): Experimental studies using itp-prone mice,(nzw x bxsb) f1. Blood 1992;79(4):942-947. 46. Hafni A, Hilmanto D, Rachmadi D, Sekarwana N. Trombocytosis in childhood relapsing nephrotic syndrome. Paediatrica Indonesiana. 2007;47(3):100-103. | - |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/88229 | - |
| dc.description.abstract | 人類醫學中，血小板的升高和實體腫瘤的生長、轉移以及不良預後有關。近年，更進一步觀察到癌症病患血小板的變化趨勢與生存時間的相關性。犬隻多中心型淋巴腫瘤，其為血液腫瘤，因此相較於實體腫瘤，對血小板的影響可能更為複雜。目前在人類醫學以及獸醫領域，對於血小板作為淋巴腫瘤的預後因子，尚未有共識。治療淋巴腫瘤的藥物中，長春新鹼，可增加周邊血液中血小板的數量。因此我們以犬淋巴腫瘤、血小板和長春新鹼之間的相互關聯，來探討犬隻多中心型淋巴腫瘤病患，施打長春新鹼前及後，血小板的表現，是否可作為預後的預測因子。本篇是回溯型研究，共納入79隻多中心淋巴腫瘤患犬。我們利用給藥前後血小板的絕對值，以及搭配給予長春新鹼後，血小板數量的增減等方式，進行各種分組，比較血小板給予長春新鹼前後的變化和預後的相關性。結果表示，治療前無血小板增多的病患；治療前或後，血小板數絕對值的多寡和預後無顯著相關；治療後，血小板的增加或是減少，和預後亦無顯著相關。而給予長春新鹼後，血小板數顯著上升，且血小板低下的病患比例相較於治療前，顯著下降。本篇結論，多中心型淋巴瘤患犬，治療前呈現血小板低下的病患，仍可以安全地使用長春新鹼作為首次化療藥物，其可顯著增加血小板數量，且降低血小板低下病患的比例。另外，在多中心淋巴腫瘤患犬，給予長春新鹼前後，血小板的絕對值以及變化幅度，不能作為預後的指標。未來相關的研究，仍需更多大型試驗來證實。 | zh_TW |
| dc.description.abstract | Canine multicentric lymphoma, being a hematologic malignancy, may have a more complex impact on platelet counts compared to solid tumors. Currently, there is no consensus in human medicine and veterinary medicine regarding platelet counts as prognostic factors in lymphoma. Vincristine, a commonly used drug in lymphoma treatment, has been shown to increase platelet counts in peripheral blood. Therefore, we conducted a study to investigate the relationship between canine multicentric lymphoma, platelet counts, and vincristine administration. We aimed to determine whether the expression of platelets before and after vincristine administration could serve as prognostic factors in dogs with multicentric lymphoma. We included 79 multicentric lymphoma dogs retrospectively. The grouping based on absolute platelet counts before and after vincristine administration, as well as the grouping based on the difference in platelet counts before and after administration, did not show any significant differences in prognosis. Additionally, we found a significant increase in platelet counts after vincristine administration. In canine multicentric lymphoma patients with baseline thrombocytopenia, vincristine can still be confidently used as a first-line chemotherapy drug. Further research is needed to determine whether the trend of platelet changes in dogs with multicentric lymphoma can serve as a prognostic indicator. | en |
| dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2023-08-09T16:06:40Z No. of bitstreams: 0 | en |
| dc.description.provenance | Made available in DSpace on 2023-08-09T16:06:40Z (GMT). No. of bitstreams: 0 | en |
| dc.description.tableofcontents | 口試委員會審定書 #
誌謝 i 中文摘要 iii ABSTRACT v CONTENTS vii LIST OF FIGURES xi LIST OF TABLES xiii LIST OF ABBREVIATIONS xiv Chapter 1 Introduction 1 Chapter 2 Objectives 9 Chapter 3 Literature review 10 3.1 Platelet count changes following vincristine injection 10 3.1.1 Platelet counts elevated after vincristine administration 10 3.1.2 Platelet peak values following vincristine administration 11 3.2 The role of platelets in tumorigenesis 12 3.3 Platelets in human oncology 13 3.4 Platelets in canine oncology 14 3.5 Assessing the prognostic value of treatment-related blood cell count changes in cancer patients 15 Chapter 4 Materials and methods 18 4.1 Study design 18 4.2 Study population and data collection 19 4.3 Inclusion and exclusion criteria 20 4.4 Treatment 21 4.5 Response and outcome 21 4.5.1 Evaluation of response 22 4.5.2 To access the outcome 22 4.6 Statistical analysis 23 Chapter 5 Results 24 5.1 Categorization based on platelet counts before treatment 24 5.1.1 Patient Demographics 24 5.1.2 Vincristine dosage 25 5.1.3 Response 26 5.2 Categorization based on platelet counts after vincristine administration 26 5.2.1 Patient Demographics 26 5.2.2 Vincristine dosage and survival analysis 28 5.2.3 Response 28 5.3 Platelet counts change after vincristine administration 29 5.4 Grouping based on the variation in platelet counts before and after treatment 30 5.5 Grouping based on the platelet counts before treatment, and further subdivided based on whether their platelet counts increased or decreased after administration of vincristine. 31 Chapter 6 Discussion 33 6.1 The relationship between the outcome and platelet counts before treatment 33 6.2 Platelet counts elevated after vincristine administration 34 6.3 The value of platelet counts or platelet count changes following administration of vincristine as a predictor of prognosis in dogs with multicentric lymphoma 36 6.3.1 Categorization based on platelet counts after vincristine administration 36 6.3.2 Grouping based on the variation in platelet counts before and after treatment 38 Chapter 7 Limitations 41 Chapter 8 Conclusions 43 Figures 44 Tables 54 References 63 | - |
| dc.language.iso | en | - |
| dc.subject | 血小板數 | zh_TW |
| dc.subject | 長春新鹼 | zh_TW |
| dc.subject | 多中心型淋巴瘤 | zh_TW |
| dc.subject | 犬 | zh_TW |
| dc.subject | canine | en |
| dc.subject | multicentric lymphoma | en |
| dc.subject | vincristine | en |
| dc.subject | platelet counts | en |
| dc.title | 以長春新鹼給藥前後的血小板數評估犬隻多中心型淋巴瘤的預後 | zh_TW |
| dc.title | Prognostic evaluation of platelet counts before and after vincristine administration in canine multicentric lymphoma | en |
| dc.type | Thesis | - |
| dc.date.schoolyear | 111-2 | - |
| dc.description.degree | 碩士 | - |
| dc.contributor.oralexamcommittee | 李繼忠;廖泰慶;劉品辰 | zh_TW |
| dc.contributor.oralexamcommittee | Jih-Jong Lee;Albert Taiching Liao;Pin-Chen Liu | en |
| dc.subject.keyword | 犬,多中心型淋巴瘤,長春新鹼,血小板數, | zh_TW |
| dc.subject.keyword | canine,multicentric lymphoma,vincristine,platelet counts, | en |
| dc.relation.page | 66 | - |
| dc.identifier.doi | 10.6342/NTU202301538 | - |
| dc.rights.note | 同意授權(限校園內公開) | - |
| dc.date.accepted | 2023-07-19 | - |
| dc.contributor.author-college | 生物資源暨農學院 | - |
| dc.contributor.author-dept | 臨床動物醫學研究所 | - |
| dc.date.embargo-lift | 2028-07-16 | - |
| Appears in Collections: | 臨床動物醫學研究所 | |
Files in This Item:
| File | Size | Format | |
|---|---|---|---|
| ntu-111-2.pdf Restricted Access | 1.15 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.